At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 296 enrolled
Drug / intervention
Dexlansoprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole
In Brief
A Phase 4 clinical trial evaluating Dexlansoprazole for Gastroesophageal Reflux Disease. Completed, enrolled 296 participants across 10 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of symptom control in gastroesophageal reflux disease (GERD) participants following treatment with dexlansoprazole.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesHong Kong, South Korea, Taiwan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMar 2015
Primary CompletionJun 2016
Study CompletionJul 2016
TodayJul 2026
First PostedJan 30, 2015
Enrollment StartMar 19, 2015
Primary CompletionJun 22, 2016
Study CompletionJul 13, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago
Interventions
Dexlansoprazoledrug
Dexlansoprazole capsules